|
|
FDADocs 5/5/2008 | 0 (0) | 52 | 0 | 0 | English
Nomination and Approval of CBER Inspectors and Product Specialists Assigned to Conduct Inspections of Biological Products SOPP 8505 APPENDIX 2
MEMORANDUM Department of Health and Human Services Public Health Service Food and Drug Administration Center for Biologics Evaluation and Research ___________________________________________________________ ... more>>
FDADocs 5/9/2008 | 0 (0) | 51 | 0 | 0 | English
Eric P. Bastings, MD, HFD-120 21-645 Myzan (MT100)
Memorandum )
Page 1 of
MEMORANDUM
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Date: From: To: Subject: May 18, 2004 Eric Bastings, MD. Russell Katz, MD 21-645 Myzan (MT100)
This submission is a new drug application (NDA) for the use of MYZAN (previou ... more>>
FDADocs 5/12/2008 | 0 (0) | 25 | 0 | 0 | English
AASLD- FDA-NIH-PhRMA January 25-26, 2006 Session I: Non-Clinical Prediction (Moderator: Patrick Weir; Reporters: Frank Sistare and John Strong) P. Wier – Integrating Liver Toxicogenomics with Clinical Pathology and Histopathology in Preclinical Studies
Q: Did you use a standard study design? A: The study was standard in terms of animals, husbandry ... more>>
FDADocs 5/9/2008 | 0 (0) | 19 | 0 | 0 | English
FDADocs 5/12/2008 | 0 (0) | 14 | 0 | 0 | English
FDADocs 5/12/2008 | 0 (0) | 32 | 0 | 0 | English
AASLD-FDA-NIH-PhRMA*- Hepatotoxicity Special Interest Group Meeting Brookside Gardens Conference Center,** Wheaton MD January 24 - 25, 2007
Issues and Conttroversiies iin DILI Issues and Con rovers es n DILI
((DIILII = drrug--iinduced lliiverr iinjjurry)) D L = d ug nduced ve n u y Wednesday, January 24, 2007
7:45 AM 8:15AM 8:20 AM CHECK-IN and CO ... more>>
ProfessionalDocument 10/11/2008 | 0 (0) | 63 | 0 | 0 | English
Boston Scientific Corporation today announced it has received approval from the U.S. Food and Drug Administration FDA to market its second-generation TAXUS Liberté Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the TAXUS Liberté stent early next month in the United States, following completion of the introduction of its ... more>>
FDADocs 5/12/2008 | 0 (0) | 32 | 0 | 0 | English
AASLD- FDA-NIH-PhRMA January 25-26, 2006 Session III: Attribution of Causality (Moderator: Leonard Seeff; Reporters: Robert Fontana and David Lilienfeld)
L. Seeff- Problems of Establishing Causality Establishing a diagnosis of DILI remains problematic in the absence of an objective and confirmatory laboratory test. Therefore, DILI is by definition ... more>>
FDADocs 5/8/2008 | 0 (0) | 44 | 0 | 0 | English
DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF THE COMMISSIONER
OFFICE OF EQUAL OPPORTUNITY COMMISSIONER OF FOOD AND DRUGS Mark B. McClellan, M.D., Ph.D. DEPUTY COMMISSIONER Lester Crawford, D.V.M., Ph.D. PRINCIPAL ASSOCIATE COMMISSIONER Murray M. Lumpkin, M.D. OFFICE OF THE ADMINISTRATIVE LAW JUDGE
PROPOSED
DIRECT ... more>>
FDADocs 5/8/2008 | 0 (0) | 366 | 4 | 0 | English
DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF THE COMMISSIONER
OFFICE OF EQUAL OPPORTUNITY COMMISSIONER OF FOOD AND DRUGS Mark B. McClellan, M.D., Ph.D. DEPUTY COMMISSIONER Lester Crawford, D.V.M., Ph.D. PRINCIPAL ASSOCIATE COMMISSIONER Murray M. Lumpkin, M.D. OFFICE OF THE ADMINISTRATIVE LAW JUDGE
DIRECTOR Georgia ... more>>
FDADocs 5/9/2008 | 0 (0) | 24 | 0 | 0 | English
Barry N. Rosloff, Ph. D. 5/14/04 NDA 21-645 (MT 100) – SUPERVISORY MEMO I am in basic agreement with the analysis of and conclusions reached by Dr. Haberny (review of 5/13/04) regarding the preclinical data for MT 100. MT 100 is a combination of two relatively old drugs, naproxen (NAP) and metoclopramide (MET). In addition to the usual practice of ... more>>
FDADocs 5/9/2008 | 0 (0) | 16 | 0 | 0 | English
SUMMARY FOR BASIS OF APPROVAL
REFERENCE NUMBER: DRUG LICENSED NAME: MANUFACTURER
92-0465
HEPATITIS A VACCINE (INACTIVATED) SMlTHKLlNE BEECHAM BlOLOGlCALS
HAVRIXTM
DRUG TRADE NAME:
HavrixTu (Hepatitis A Vaccine, Inactivated) is a whole-virion formaldehyde inactivated alum-adsorbed vaccine indicated for active . immunization against hepatitis A ... more>>
GovernmentDocs 5/4/2008 | 0 (0) | 34 | 0 | 0 | English
j
i.
Summary for Basis of Approval
Reference Number: 90-0689 Dnra Licensed Name: Haemophi1us.b Conjugate Vaccine (Tetanus Toxoid Conjugate) Druq Trade Name: ActHlB
Manufacturer: Pasteur Merieux Serums & Vaccins, S.A.
'
Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), ActHIBTM, composed is of the purified capsular polysaccharide isola ... more>>
FDADocs 5/9/2008 | 0 (0) | 27 | 0 | 0 | English
FDADocs 5/12/2008 | 0 (0) | 27 | 0 | 0 | English
|